Mukund Paravasthu - 03 Mar 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Chief Operating Officer
Signature: Steven Robbins, as attorney in fact for Paravasthu, Mukund
Issuer symbol: NVCR
Transactions as of: 03 Mar 2026
Net transactions value: -$667,214
Form type: 4
Filing time: 05 Mar 2026, 16:31:19 UTC
Previous filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Paravasthu Mukund	Chief Operating Officer	C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE	Steven Robbins, as attorney in fact for Paravasthu, Mukund	05 Mar 2026	0002039078

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Award		+45,112	+59%	$0.000000^*	121,455	03 Mar 2026	Direct	F1
transaction	NVCR	Ordinary Shares	Sale	$71,543	-5,377	-4.4%	$13.31	116,078	04 Mar 2026	Direct	F2, F3
transaction	NVCR	Ordinary Shares	Sale	$595,670	-43,246	-37%	$13.77	72,832	05 Mar 2026	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Stock Option (Right to Buy)	Award		+7,518		$0.000000^*	7,518	03 Mar 2026	Ordinary Shares	7,518	$13.30	Direct	F5
transaction	NVCR	Stock Option (Right to Buy)	Award		+58,488	+778%	$0.000000^*	66,006	03 Mar 2026	Ordinary Shares	58,488	$13.30	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3	This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
F4	This transaction was executed in multiple trades at prices ranging from $13.74 USD to $14.07 USD; the price reported above reflects the weighted average sale price.
F5	Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.